Trial aims to tame harsh chemo gut side effects
NCT ID NCT04249622
Summary
This study tested whether the antibiotic rifaximin could reduce severe stomach pain, diarrhea, and other gut problems caused by a standard breast cancer drug combination. It involved 20 women with early-stage HER2-positive breast cancer who were experiencing these side effects. The goal was to see if rifaximin could ease symptoms enough to allow patients to continue their cancer treatment on schedule without dose reductions or delays.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
Conditions
Explore the condition pages connected to this study.